Author

R. Maziarz

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Large B-Cell Lymphoma After CD19 CAR-T Failure: Updated Real-World Outcomes, Prognostic Factors, and Prediction Models.

Background Outcomes after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy failure in relapsed or refractory large B-cell lymphoma (LBCL) remain poor, and prognostic tools to guide subsequent management are limited. We evaluated real-world outcomes after CAR-T failure and developed clinical prediction mod...

S. Kungwankiattichai, Sanjog Bastola, Manoj Rai et al. · Transplantation and Cellular... · 0 citations

Open access Jul 2026

Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.

The results demonstrate the importance of continuous patient monitoring and management during CAR-T therapy and demonstrate an evolving treatment landscape, including more aggressive management of CRS and interest in preventive therapies for CRS and ICANS.

M. Frigault, R. Maziarz, T. Amoloja et al. · Transplantation and Cellular... · 0 citations

Open access Aug 2026

Challenges with expansion of cell and gene therapy: A call for system-level action

Cellular and gene therapy (CGT) has fundamentally reshaped the treatment landscape for a growing range of malignant and non-malignant diseases. Yet the rapid expansion of CGT has also exposed critical institutional and system-level pressures, including constraints in infrastructure and workforce capacity, product manuf...

Jeffery J. Auletta, Á. Urbano-Ispizua, R. Maziarz et al. · Transplantation and Cellular... · 0 citations